Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 05 October 2012 | By Alexander Gaffney, RAC
The European Commission has released new amendments to the EU's recent pharmacovigilance legislation after it said it was made aware of several potential loopholes through which dangerous products could escape monitoring.
In a 4 October statement, the EC said the changes were mostly done as a result of a recent scandal involving the anti-diabetes drug Mediator, which was removed in most countries but remained on the market in France. It has been implicated in thousands of adverse events and hundreds of deaths, and EU officials said it, "Revealed some weaknesses in the EU system concerning pharmacovigilance."
In response to stress testing, EC said it had released a handful of new procedures aimed at closing down potential loopholes in the legislation.
Sponsors of marketed products will meanwhile be required to justify all withdrawals of a product from the market, as well as suspensions or non-renewals of marketing authorizations.
"[The new rules] will lead to strengthened monitoring of additional categories of medicinal products. Patients and health professionals will recognize these medicines thanks to a standard black symbol, and an explanatory statement about the product's characteristics," explained the EC in a statement. "That statement will encourage all users to report suspected adverse reactions to these medicinal products."
In addition to requiring additional monitoring and notification procedures, the EC said the new amendments will allow for automatic assessments of pharmacovigilance issues at the EU level if serious safety concerns are raised. In addition, sponsors required to conduct post-approval safety studies will also have their products included in a list of medicines which the EC said will be subject to increased monitoring.
The new rules are scheduled to come into full effect by October 2013.
Tags: European Commission, Latest News, pharmaceutical, drug, pharmacovigilance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.